Simultaneously, ITGA9 is obviously up-regulated in already-developed drug-resistant colon cancer cells, whereas α9 is reported to be a promising target candidate for overcoming methotrexate resistance in colon cancer (95). This evidence concerns the gene ITGA9 and colonic neoplasm.